Oncos Therapeutics Ltd.

Oncos Therapeutics develops novel cancer therapies based on its next generation oncolytic viruses. Since the onset of our Advanced Therapy Access Program in 2007, 200 patients have undergone tailored treatment suggesting strong safety and efficacy. The program is based on extensive scientific research at the University of Helsinki and serves as the foundation for our ongoing clinical development.